Cargando…
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
Outcomes for pancreatic cancer (PC) patients remain strikingly poor with a 5‐year survival of less than 8% due to the lack of effective treatment modalities. Here, a novel precision medicine approach for PC treatment is developed, which is composed of a rationally designed tumor‐targeting ICAM1 anti...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7740099/ https://www.ncbi.nlm.nih.gov/pubmed/33344137 http://dx.doi.org/10.1002/advs.202002852 |